Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Investing.com - PTC Therapeutics (NASDAQ: PTCT) reported second quarter EPS of $-0.83, $0.23 better than the analyst estimate of $-1.06. Revenue for the quarter came in at $178.9M versus the consensus estimate of $171.74M.
Guidance
PTC Therapeutics sees FY 2025 revenue of $650.00M-$800.00M versus the analyst consensus of $1.75B.
PTC Therapeutics’s stock price closed at $50.34. It is up 13.81% in the last 3 months and up 55.13% in the last 12 months.
PTC Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See PTC Therapeutics’s stock price’s past reactions to earnings here.
According to InvestingPro, PTC Therapeutics’s Financial Health score is "excellent performance".
Check out PTC Therapeutics’s recent earnings performance, and PTC Therapeutics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar